Human Fc gamma receptors and complement component C1q (FcγR and C1q)

Human Fc gamma receptors (FcγRs) and complement component C1q are essential mediators of the effector functions of immunoglobulin G (IgG) antibodies, serving as the link between the adaptive and innate immune systems. FcγRs are a family of cell-surface glycoproteins, including the activating receptors FcγRI (CD64), FcγRIIa (CD32a), and FcγRIIIa (CD16a), as well as the inhibitory receptor FcγRIIb (CD32b), which are expressed on various immune cells such as natural killer (NK) cells, macrophages, and neutrophils. Complement component C1q is the recognition protein of the classical complement pathway that binds to the Fc region of antibodies within immune complexes to initiate a proteolytic cascade. Together, these molecules facilitate antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). In clinical practice, these molecules are the primary mechanisms by which therapeutic monoclonal antibodies eliminate tumor cells or pathogens. In diseases like cancer, drugs are often engineered to enhance binding to activating FcγRs or C1q to increase potency, while in autoimmune conditions, the goal may be to block these interactions to prevent tissue damage. Notable therapeutic challenges include managing cytokine release syndrome and ensuring that the balance between activating and inhibitory signals is maintained to avoid excessive inflammation or autoimmunity. Genetic polymorphisms in FcγRs, such as the FCGR3A-V158F variant, are known to influence the clinical efficacy of monoclonal antibodies like rituximab, making them important biomarkers for patient selection. Recent drug development efforts have also focused on direct inhibitors of C1q, such as ANX005, to treat neurodegenerative and autoimmune disorders where complement activation is pathological.

Other names

Fc gamma receptorsFcγRComplement C1qCD64CD32CD16C1q complexIgG Fc receptors

Therapeutic antibodies bind to target antigens via their Fab regions and subsequently recruit FcγRs or C1q via their Fc regions to trigger effector functions like ADCC, ADCP, or CDC; direct inhibitors can also block these molecules to prevent pathological activation.